Worldwide Interest in Global Access to Drugs

Banta, H.D.

doi:10.1001/jama.285.22.2844

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, generic medicines cost a fraction of the prices of branded pharmaceuticals. For example, available figures show that a year's treatment of HIV with generic drugs cost US$130 (£65; E170) compared with the US$10,000 cost for the brand named version (Banta 2008(Banta , 2845. Positive CSR actions may include voluntary licensing to enable the generic industries to produce patented medicines and the research and development of drugs for tropical diseases.…”

Section: Pricingmentioning

confidence: 99%

Pharmaceutical companies and access to medicines – social integration and ethical CSR resolution of a global public choice problem

Osuji

Umahi

2012

Journal of Global Ethics

View full text Add to dashboard Cite

This article argues that effective corporate social responsibility (CSR) of multinational pharmaceutical companies in developing countries should reflect context, opportunity, proximity, time and impact in accordance with the social integration and ethical approaches to CSR. It proposes a CSR model expressed as CSR¼COPTI+SI+E, which acknowledges access-to-medicines as a matter in the global public domain, a public choice problem and a moral responsibility issue for multinational pharmaceutical companies. This model recognises the globalisation of the principle of humanity in communities of place and communities of interest as highlighted by the Global Economic Ethic Manifesto 2009 as an integral part of the responsibilities of multinational pharmaceutical companies. The model reflects a global application of the concept of disadvantaged consumer already known to some national laws. The article suggests an access-to-medicines CSR framework for pharmaceutical companies which may include pricing, patents, testing and clinical trials, research and development, joint public private initiative and appropriate use of drugs.

show abstract

Section: Pricingmentioning

confidence: 99%

Pharmaceutical companies and access to medicines – social integration and ethical CSR resolution of a global public choice problem

Osuji

Umahi

2012

Journal of Global Ethics

View full text Add to dashboard Cite

show abstract

List of Selected References

2006

The Law and Ethics of the Pharmaceutical Industry

View full text Add to dashboard Cite

Human Rights and Global Health: A Research Program

2005

View full text Add to dashboard Cite

One-third of all human lives end in early death from poverty-related causes. Most of these premature deaths are avoidable through global institutional reforms that would eradicate extreme poverty. Many are also avoidable through global health-system reform that would make medical knowledge freely available as a global public good. The rules should be redesigned so that the development of any new drug is rewarded in proportion to its impact on the global disease burden (not through monopoly rents). This reform would bring drug prices down worldwide close to their marginal cost of production and would powerfully stimulate pharmaceutical research into currently neglected diseases concentrated among the poor. Its feasibility shows that the existing medical-patent regime (trade-related aspects of intellectual property rightsFTRIPSFas supplemented by bilateral agreements) is severely unjustFand its imposition a human-rights violation on account of the avoidable mortality and morbidity it foreseeably produces.

show abstract

Worldwide Interest in Global Access to Drugs

Cited by 4 publications

References 0 publications

Pharmaceutical companies and access to medicines – social integration and ethical CSR resolution of a global public choice problem

Pharmaceutical companies and access to medicines – social integration and ethical CSR resolution of a global public choice problem

List of Selected References

Human Rights and Global Health: A Research Program

Contact Info

Product

Resources

About